FAQ: Kairos Pharma's ENV105 Phase 1 Data Presentation at World Lung Cancer Conference

What is the main announcement from Kairos Pharma?

Kairos Pharma announced it will present initial Phase 1 data for ENV105 in non-small cell lung cancer at the World Lung Cancer Conference in September 2025. The presentation will focus on the combination therapy of ENV105 with osimertinib for advanced EGFR-mutated non-small cell lung cancer patients.

Who is presenting the Phase 1 data and what is the presentation title?

Principal Investigator Dr. Karen Reckamp will present the data. Her presentation is titled “Combination of Osimertinib and Carotuximab for Advanced, EFGR-Mutated Non-Small Cell Lung Cancer Patients” at the World Lung Cancer Conference.

When and where is the World Lung Cancer Conference taking place?

The conference is scheduled for September 6-9, 2025, at the Fira de Barcelona Gran Via in Barcelona, Spain, where the ENV105 Phase 1 data will be presented.

What is ENV105 and how does it work?

ENV105 is Kairos Pharma’s lead antibody candidate that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. It aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.

What is the primary objective of the Phase 1 trial for ENV105?

The open-label trial’s primary objective is to evaluate the safety and tolerability of the combination therapy of ENV105 with osimertinib for advanced EGFR-mutated non-small cell lung cancer patients.

What other clinical trials is ENV105 currently involved in?

ENV105 is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer in addition to the Phase 1 trial for lung cancer, both aimed at addressing significant unmet medical needs in cancer treatment.

Where can investors find more information about Kairos Pharma?

The latest news and updates relating to Kairos Pharma (KAPA) are available in the company’s newsroom at https://ibn.fm/KAPA, and the full press release can be viewed at https://ibn.fm/5JjZJ.

What is Kairos Pharma’s focus and approach to cancer therapeutics?

Kairos Pharma is a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company is based in Los Angeles, California, and trades on NYSE American under the symbol KAPA.